Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme

Preexisting humoral immunity to recombinant adeno-associated virus (AAV) vectors restricts the treatable patient population and efficacy of human gene therapies. Approaches to clear neutralizing antibodies (NAbs), such as plasmapheresis and immunosuppression, are either ineffective or cause undesira...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmore, Zachary C., Oh, Daniel K., Simon, Katherine E., Fanous, Marco M., Asokan, Aravind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566709/
https://www.ncbi.nlm.nih.gov/pubmed/32941184
http://dx.doi.org/10.1172/jci.insight.139881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566709/
https://www.ncbi.nlm.nih.gov/pubmed/32941184
http://dx.doi.org/10.1172/jci.insight.139881

Ejemplares similares